Clinical trial failure

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

2 weeks ago talkbio0Tagged Autoimmune Diseases, Clinical Research, Clinical trial failure, daisy, Imaavy, Johnson and Johnson, Nipocalimab, Phase 2a Trial, Rheumatoid Arthritis

Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

2 weeks ago talkbio0Tagged AMX0035, Amylyx, Amyotrophic Lateral Sclerosis, Clinical trial failure, Discontinuation (procedure), disease program, Infrequent, Placebos, Progressive, Relyvrio, Supranuclear paralysis

Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

1 month ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints

Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps

2 months ago talkbio0Tagged Blepharitis, Clinical trial failure, Drug Development, MR-139, ophthalmic preparation, Phase 3 Clinical Trials, pimecrolimus, pipeline, strategic review, Viatris

Viatris; ophthalmic drug; Phase 3 study; blepharitis; MR-139; clinical trial failure; drug development; pimecrolimus; pipeline; strategic review

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

2 months ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

Taiho’s Investigational DMD Therapy Misses Primary Endpoint in Phase 3 Trial

2 months ago talkbio0Tagged Clinical trial failure, Muscular Dystrophy, Duchenne, Otsuka Holdings, pizuglanstat, REACH-DMD study, Taiho, TAS-205

Taiho; Duchenne muscular dystrophy; DMD; pizuglanstat; TAS-205; Phase 3 trial; clinical trial failure; REACH-DMD study; Otsuka Holdings

Vertex Lays Off 125 Staffers, Shrinks Rhode Island Campus After Diabetes Therapy Setback

3 months ago talkbio0Tagged cell-device combo, Clinical trial failure, Diabetes Therapy, facility consolidation, layoffs, Rhode Island, VX-264

Vertex Pharmaceuticals; layoffs; Rhode Island; diabetes therapy; VX-264; cell-device combo; clinical trial failure; facility consolidation

iTeos to Shut Down Operations After TIGIT Therapy Setback

3 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial

8 months ago talkbio0Tagged Agonist, Amyotrophic Lateral Sclerosis, Clinical trial failure, Denali, DNL343, Eukaryotic Initiation Factor-2B, HEALEY, Neurodegenerative Disorders

Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases